PCSA NASDAQ
Processa Pharmaceuticals, Inc.
1W: -12.5%
1M: -23.3%
3M: -23.3%
YTD: -45.0%
1Y: -67.5%
3Y: -98.8%
5Y: -100.0%
$1.61
-0.01 (-0.62%)
Weekly Expected Move ±11.9%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships4
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-06-17
Earliest Filing
2022-03-24
Latest Filing
partner: 2
acquirer: 1
investor: 1
Counterparties (Filed by PCSA)
4 relationshipsCompanies named in PCSA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| PROCESSA PHARMACEUTICALS, INC. | PCSA | acquirer | Company selling common stock to investor | 2022-03-24 | View |
| LINCOLN PARK CAPITAL FUND, LLC | — | investor | Investor purchasing up to $15,000,000 of common stock | 2022-03-24 | View |
| Processa Pharmaceuticals, Inc. | PCSA | partner | Licensee entering into a license agreement for pharmaceutical rights | 2021-06-17 | View |
| Ocuphire Pharma, Inc. | — | partner | Licensor granting rights to Processa Pharmaceuticals, Inc. | 2021-06-17 | View |
Mentioned As Counterparty
1 mentionsOther companies that named PCSA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-07-29 | Material Agreement; Termination of Agreement; Acquisition/Disposition; Unregistered Equity Sales; Of | Agreement Acquisition | View |
| 2026-04-30 | Officer/Director Change; Exhibits | View | |
| 2026-02-19 | Termination of Material Definitive Agreement; Financial Statements and Exhibits | View | |
| 2026-01-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-15 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-09-16 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-09-12 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-09-10 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-09-02 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-08-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-14 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-08-08 | Notice of Delisting or Transfer; Financial Statements and Exhibits | View | |
| 2025-08-07 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-07-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-18 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-07-15 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-07-01 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-06-30 | Entry into Material Definitive Agreement; Submission of Matters to a Vote of Security Holders; Finan | Agreement | View |
| 2025-06-18 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR